Terns Pharmaceuticals (NASDAQ: TERN)
Terns Pharmaceuticals Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Terns Pharmaceuticals Company Info
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.
News & Analysis
Why Shares of Terns Pharmaceuticals Soared This Week
The company is showing progress toward a NASH therapy.
The Promises Behind Terns' Multi-Pronged Pipeline
This pharma may be a newcomer to the stock market, but it has several innovative drugs in development for a common condition with no current treatments approved.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.